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Genome-wide levels of DNA methylation vary between tissues, and compared with other tissues, the placenta
has been reported to demonstrate a global decrease in methylation as well as decreased methylation of
X-linked promoters. Methylation is one of many features that differentiate the active and inactive X, and it
is well established that CpG island promoters on the inactive X are hypermethylated. We now report a
detailed analysis of methylation at different regions across the X in male and female placenta and blood. A
signiﬁcant (P < 0.001) placental hypomethylation of LINE1 elements was observed in both males and females.
Relative to blood placental promoter hypomethylation was only observed for X-linked, not autosomal promo-
ters, and was signiﬁcant for females (P < 0.0001) not males (P 5 0.9266). In blood, X-linked CpG island pro-
moters were shown to have moderate female methylation (66% across 70 assays) and low (23%)
methylation in males. A similar methylation pattern in blood was observed for 20% of non-island promoters
as well as 50% of the intergenic or intragenic CpG islands, the latter is likely due to the presence of unanno-
tated promoters. Both intragenic and intergenic regions showed similarly high methylation levels in male and
female blood (68 and 66%) while placental methylation of these regions was lower, particularly in females.
Thus placental hypomethylation relative to blood is observed globally at repetitive elements as well as
across the X. The decrease in X-linked placental methylation is consistently greater in females than males
and implicates an inactive X speciﬁc loss of methylation in the placenta.
INTRODUCTION
The human placenta is a unique organ in that while it is critical
for in utero healthy development, it is no longer needed after
birth. The placenta has been shown by HPLC to have 20%
fewer 5-methylcytosines compared with the vast majority of
other tissues (1–3). Regions previously shown to have
reduced placental methylation include repeat elements (Alus,
LINEs, and satellites) and several X-linked genes with CpG
island associated promoters (2,4–7). Methylation occurs at
CpG dinucleotides in mammals, and the human genome con-
tains over 27 million CpGs, 70% of which are typically
methylated (1,8). CpGs are not evenly distributed across the
genome, with regions of high CpG density known as CpG
islands often found at promoters. The majority of CpG
islands at promoters are unmethylated and methylation of
these islands is typically linked with gene silencing (9). The
distinction between CpG islands and non-islands is based on
sequence composition and the criteria traditionally used to
deﬁne a CpG island are GC content and observed CpG to
expected CpG ratio (10–12).
Of the approximately 1.2 million CpGs on the human
X chromosome only 5% are located within CpG islands [Uni-
versity of California Santa Cruz (UCSC) Genome Browser],
and 50% of these islands are associated with known promo-
ters, while the remaining islands are equally distributed within
gene bodies and between genes across the X chromosome
(12). With the exception of genes which escape X inactivation,
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males and partial methylation in females (10,13). We term this
classic methylation pattern of active X (Xa) hypomethylation
and inactive (Xi) hypermethylation as MeXiP (Methylation of
Xi Promoters).
There is some conﬂicting data as to the methylation status
of the X chromosome as a whole. Using methylation-sensitive
restriction enzyme analysis, the Xi appears to be hypomethy-
lated compared with the Xa, conversely, in situ nick trans-
lation data demonstrated the Xa to be hypomethylated
compared with the Xi and antibody staining demonstrated no
difference between the Xs (14–16). Southern analysis of a
limited number of X-linked single copy loci and two tandem
repeats have suggested that the Xa is hypermethylated relative
to the Xi, although non-promoter methylation levels were high
and variable (17–20). Jones discussed such patterns as a
‘methylation paradox’ and proposed that hypermethylation
of gene bodies might be caused by gene transcription (21).
This hypothesis is supported by a recent microarray study
that found overall hypermethylation of the X in males relative
to females (22). Furthermore, using single-nucleotide poly-
morphisms in clonal lymphoblast cell lines, Hellman and
Chess (23) were able to speciﬁcally demonstrate that the Xa
has over two times more methylation than the Xi, particularly
within gene bodies.
Our comparison of methylation between placenta and blood
has revealed global LINE1 placental hypomethylation, as well
as placental hypomethylation of X-linked promoters but not
autosomal promoters. Using a combination of Illumina Gold-
enGate methylation analysis and pyrosequencing, three differ-
ent types of X-linked regions (promoter, intragenic and
intergenic) were shown to have less methylation in placenta
compared with blood. This hypomethylation was greater in
female than male placenta suggesting the difference is predo-
minantly due to the Xi. These ﬁndings suggest a different
system for the establishment or maintenance of methylation
on the active and inactive X chromosomes.
RESULTS
Placental hypomethylation is speciﬁc to X-linked
promoters and repetitive elements
Average LINE1 methylation across the genome, as determined
by pyrosequencing, displayed signiﬁcant (P ¼ 0.0009) placen-
tal hypomethylation compared with blood in both females
(32% lower methylation) and males (36% lower methylation)
(Fig. 1A). To determine if the placental hypomethylation pre-
viously reported at X-linked promoters also extended to auto-
somal promoters, the Illumina GoldenGate panel was used to
assess the level of promoter methylation at 1421 promoter
sites on the autosomes and 84 sites on the X chromosome in
both blood and placenta (Fig. 1B). Average autosomal methyl-
ation levels showed no signiﬁcant difference (P ¼ 0.05)
between male and female blood and placenta, whereas
dramatic sex and tissues differences were observed for the
X chromosome (P , 0.001). The X chromosomes were
examined in more detail to determine the extent of the
X-linked placental hypomethylation.
CpG density inﬂuences the methylation patterns
of X-linked promoters
The Manhattan Hierarchical Cluster Metric (Illumina Bead-
Studio) separated the 29 samples analyzed into four clusters
that corresponded to male blood, female blood, male placenta
and female placenta (Fig. 2). To assess the impact of CpG
density, we utilized the expanded nomenclature of Weber
et al. (10) to include an intermediate CpG density category
(IC) in addition to the high density (HC) and low density
(LC) categories (see Materials and Methods). In blood, 51 of
84 X-linked promoter assays examined demonstrated moder-
ate methylation in females (average beta-value of 0.67) and
negligible methylation in males (average beta-value of 0.08),
the anticipated pattern for X-linked CpG island promoters of
genes subject to inactivation, MeXiP (labeled group 1 on
Fig. 2). MeXiP assays tended to have less methylation in the
placenta. One-third of all assays demonstrated high methyl-
ation in both male and female blood (group 3 on Fig. 2) and
could be subdivided into those with generally less placental
methylation (group 3a) and those that were also highly methyl-
ated in placenta (group 3b). A small number of assays demon-
strated extremely low methylation in both males and females
(group 2 on Fig. 2). As shown in the pie charts on Figure 2,
LC assays were found in each group. However, the majority
of assays in LC regions were located within group 3; while
the promoters displaying MeXiP were generally in HC and
Figure 1. Reduced placental methylation found at LINE1 repetitive elements
and promoters on the X chromosome. Average level of methylation for female
blood (grey), female placenta (grey hatched), male blood (white) and male pla-
centa (white hatched) are shown with error bars (one standard deviation) based
on the average sample deviation at a single site. Signiﬁcance calculated using
Mann–Whitney test with P , 0.001 ( ). (A) LINE1 percent methylation as
determined by pyrosequencing at LINE1 repetitive elements across the
genome. (B) Illumina Golden Gate Promoter methylation array data averaged
separately for 1421 sites on the autosomes and 84 X-linked sites. Beta-values
represent average percent methylation.
Human Molecular Genetics, 2009, Vol. 18, No. 19 3545Figure 2. Heatmap of methylation levels at 84 sites across the X chromosome demonstrates that the majority of X-linked promoter assays demonstrate MeXiP
and are of high and intermediate CpG density while low CpG density assays tend to be highly methylated. Methylation levels determined by Illumina Golden
Gate promoter methylation array are represented as a gradient from red (high methylation) to green (low methylation). BeadStudio software used the Manhattan
Hierarchical Cluster Metric to group samples that were separated by tissue and sex (coding of samples as follows: yellow ¼ female placenta, blue ¼ male pla-
centa, dark blue ¼ male blood, orange ¼ female blood). Assays were visually divided into four groups based on methylation trends. Group 1 shows high female
methylation and low male in blood (MeXiP), group 2 shows low methylation in all samples and group 3 shows high methylation in both male and female blood.
Group 3a had variable placenta methylation while group 3b had high methylation in the placenta. The CpG density of each assay, high (HC) (black square),
intermediate (IC) (dark grey circle) or low (LC) (light grey triangle), is shown to the right and the assay names to the left of the heatmap. The percent of
assays within each group based on CpG density is shown as a pie chart to the far right of the heatmap.
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display MeXiP can be found in Supplementary Material,
Table S1. The majority of these exceptions can be explained
by expression pattern or proximity to repetitive elements,
however, there are some CpG island promoter assays with
no obvious reason for deviation from the MeXiP pattern.
For regions that display MeXiP the methylation provides a
means to examine the distance over which promoter methyl-
ation is correlated with inactivation status. Plotting DNA
methylation levels against the distance from the transcription
start site (TSS) for each promoter CpG density class, sex
and tissue (Supplementary Material, Fig. S1) demonstrated
that a majority of HC assays outside the 2700 to þ200 bp
promoter window had nearly complete methylation in both
tissues (10). The HC and IC regions examined were not sig-
niﬁcantly different from each other in either sex or tissue
and thus, both will subsequently be referred to as CpG
islands. Non-island (LC) assays showed no relationship
between methylation and the distance from the TSS.
DNA methylation is female-speciﬁc at X-linked island
promoters but is consistently high at intragenic
and intergenic regions
The Illumina GoldenGate panel only provided data on CpGs in
promoters, so pyrosequencing was used to conﬁrm the level of
methylation at promoters of all three CpG densities, as well as
to determine methylation at intragenic and intergenic regions
(10 assays each). Another advantage to pyrosequencing is a
larger number of CpGs within a small region can be examined.
The complete data set of 30 assays for six blood samples and
six placenta samples (two sites sampled per placenta) for a
total of 5076 data points is shown in Supplementary Material,
Figure S2. There was more variation in methylation levels
between placental samples and between sites of the same pla-
centa than for blood samples across all males and females. An
individual CpG in a region was on average only 7% different
from the average of all CpGs assayed from that region, with
only one assay (rs1212068) showing an average difference
of more than 12% due to a single outlier CpG. Therefore,
the average percent methylation for each assay was compared
in Figure 3 for the six male and six female blood as well as all
placenta samples. Assays were subdivided into panels for
location in promoters, intragenic or intergenic regions and
ordered according to the CpG density (HC/IC/LC) of the
region. Consistent with the Illumina GoldenGate promoter
methylation data, female placenta showed an average of
16% less methylation compared with female blood, whereas
male placenta showed an average of only 4% less methylation
compared with male blood.
Ten promoter regions of varying CpG density were exam-
ined by pyrosequencing to determine if they followed
MeXiP (Fig. 3A). One assay, NDP, stood out as an outlier
with low methylation (below 20%) in all samples despite car-
riers manifesting Norrie’s disease with X chromosome
rearrangements suggesting that NDP undergoes X inactivation
(24). For other assays the methylation patterns of the island
promoter assays were very similar, with the highest methyl-
ation being detected in female blood which averaged 38%, fol-
lowed by female placenta which averaged 21%. Male blood
Figure 3. X-linked CpG island promoters show female-speciﬁc methylation,
whereas methylation is high in both X-linked intragenic and intergenic
regions in females and males. Average percent methylation from 30 pyrose-
quencing assays for six female blood (grey), six female placenta (grey
hatched), six male blood (white) and six male placenta (white hatched). Each
placenta was sampled from two sites within a single placenta for a total
of 12 placental samples. Assays are separated into CpG density, high (HC),
intermediate (IC) and low (LC), from the left to the right, by vertical lines.
(A) Promoter assays; (B) intragenic assays; (C) intergenic assays. The region
assayed is listed below each set of averages. Signiﬁcance calculated using
Mann–Whitney test with P , 0.01 ( ). Error bars are one standard deviation.
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10%. One of the three non-island promoters examined
(ILRAPL1) showed methylation levels comparable to island
promoters in blood, while the others showed higher methyl-
ation levels than the island promoter assays in all samples.
Therefore, in both the Illumina GoldenGate panel and the pyr-
osequencing data the HC and IC promoter assays examined
showed MeXiP as did a subset of LC promoters.
Intragenic regions analyzed included both exons and introns
which showed similar patterns of methylation. For LC intra-
genic and intergenic regions there was an average of 80 and
70% methylation, respectively, across all assays with less
difference observed between sexes for blood than for placenta.
While ﬁve of the intragenic and intergenic island assays
showed a similar high methylation, others (ARHGAP6,
BHLHB9, CpG145, CpG36 and CpG70) were much more
reminiscent of the MeXiP pattern of methylation of the promo-
ter assays. Examination of the histone modiﬁcations present in
the regions of CpG36 and BHLHB9 using the histone modiﬁ-
cation tracks of UCSC Genome Browser showed that they
possess histone modiﬁcation patterns reminiscent of a promo-
ter (12,25,26). Thus the MeXiP pattern may provide an
additional approach to determine the location of unannotated
promoters on the X chromosome.
Two assays, ARHGAP6 and BHLHB9, showed hyper-
methylation of the placenta compared with blood in males
and females and are located within 2 kb of an alternative pro-
moter for an isoform of their respective genes and thus may
reﬂect tissue-speciﬁc methylation. One male blood sample
showed a methylation level very different from the others
for ARHGAP6 at all ﬁve CpG sites in the assay, despite sex-
normal methylation at all other loci examined. This could
potentially reﬂect allele-speciﬁc methylation in this individual
(27). Overall, with the exception of likely unannotated promo-
ters, intragenic and intergenic assays were heavily methylated
independent of CpG density. Less methylation was still
observed in the placenta, particularly in female samples,
suggesting that the Xi shows more placental hypomethylation
than the Xa.
The inactive X has less methylation than the active X
in placenta compared with blood
To distinguish how the Xa and Xi differed in methylation the
assumption was made that males and females would have
equivalent methylation on their respective Xa’s and, therefore,
the methylation of the male X was used as the value for the Xa
in both males and females. The Xi methylation level was then
calculated as described in Materials and Methods. The differ-
ence in methylation levels between blood and placenta for
each pyrosequencing assay is shown for the Xa and the Xi
in Supplementary Material, Figure S3 and summarized accord-
ing to location and CpG density in Table 1. The assays located
in promoters on average had 3% less methylation on the Xa
in placenta compared with blood and a signiﬁcant (P , 0.05)
decrease in methylation on the Xi of 35%. The island-
containing promoters had limited Xa methylation and thus
would not be anticipated to differ in placenta. The non-island
promoters, as well as the intragenic and intergenic regions,
however, showed equivalent Xa and Xi methylation in
blood, whereas in placenta the Xi showed 2-fold less methyl-
ation relative to the Xa. In placenta, the Xa did appear to show
a slight decrease in methylation compared with blood,
however, this was not signiﬁcant, whereas the decrease in
methylation from the Xi was signiﬁcant in all regions (P ,
0.01). The methylation difference was also greatest from
Table 1. Average percent methylation as determined by pyrosequencing at promoter, intragenic and intergenic regions across the X chromosome in blood and






































Promoter 9 23 44 64 0.35  20 24 29 0.68 23 235  
HC 5 8 38 68 0.12 12 24 35 0.35 4 233
IC
f 1 12 37 62 0.20 3 8 13 0.19 210 249
LC 3 50 55 59 0.85 38 31 25 1.52 213 234
Intragenic 8 89 86 83 1.08  82 73 63 1.30   27 219  
HC
g 1 91 90 90 1.01 65 62 60 1.09 226 230
IC
g 2 92 91 90 1.03 88 81 73 1.21 24 216
LC 5 88 83 78 1.12 83 71 60 1.39 25 219
Intergenic 10 58 62 65 0.88 43 38 33 1.29  215 232   
HC 3 29 42 56 0.52 11 18 25 0.43 218 231
IC 2 46 59 71 0.65 32 36 41 0.77 215 230
LC 5 79 74 69 1.15 66 50 34 1.92 213 234
aNumber of independent regions assessed as shown on Figure 3, excluding the genes noted below (NDP, ARHGAP6 and BHLHB9) and discussed in the
text.
bMethylation in males was used as Xa methylation level.
cXi methylation calculated assuming that Xa in female is equivalent to Xa in males.
dXa and Xi were compared to determine if they differed in blood and placenta. Signiﬁcance calculated using Mann–Whitney test with signiﬁcance shown as P ¼
0.01 to 0.05 ( ) and P ¼ 0.001 to 0.01 (  ).
eBlood and placenta were compared to determine if the Xa and Xi differed in their tissue speciﬁc methylation levels. Signiﬁcance calculated using Mann–Whitney
test with signiﬁcance shown as P ¼ 0.001 to 0.01 (  ) and P , 0.001 (   ).
fNDP removed from the average as it showed low methylation in all samples.
gARHGAP6 and BHLHB9 removed from the average as both appeared to be an alternative promoter for an isoform of their respective genes.
3548 Human Molecular Genetics, 2009, Vol. 18, No. 19females overall for X-linked assays on the Illumina Golden-
Gate panel (Supplementary Material, Fig. S4), further support-
ing that the majority of the methylation decrease observed in
placenta is from differences in methylation of the Xi.
DISCUSSION
Previous studies have shown a global reduction in DNA
methylation of placenta compared with the vast majority of
other tissues and a speciﬁc placental hypomethylation of
repetitive elements and X-linked promoters (1–3,28). In this
study, a comparison of autosomal and X-linked promoters
showed that methylation of placental promoters was strikingly
reduced only on the X chromosome, particularly in females,
with the placenta showing an average of 27% less promoter
methylation than blood in females and 8% less in males.
The greater placental hypomethylation observed in females
implicates an Xi-speciﬁc methylation decrease. To calculate
Xi methylation we make the assumption that the male and
female Xa are equivalently methylated, a common assumption
in the study of X inactivation. For methylation this assumption
has been supported by studies of the Xi isolated in mouse/
human somatic cell hybrids, or distinguished by SNPs in
clonal female population of cells; however, differences at indi-
vidual loci could arise due to hormonal differences, or the
different gene content of the sex chromosomes (23,29).
In general, IC regions are not classiﬁed as CpG islands,
however, in this study HC and IC regions were not signiﬁ-
cantly different in their methylation levels suggesting that
functionally on the X chromosome IC regions behave as
CpG islands. For promoters demonstrating MeXiP, we
propose that the small degree of methylation seen in males
(averaging 8%) is not biologically relevant in preventing
expression from the Xa, whereas the higher level observed
in females reﬂects the additional methylation on the Xi
which is associated with gene silencing. Methylation levels
varied between promoters and were also dependent on the
assay technology. Nonetheless, consistent with a recent
study, it is clear that for individual gene promoters silencing
on the Xi can be maintained with substantially less than
100% methylation (30).
Figure 4 summarizes the changes in placental X-linked
methylation and illustrates that not only is placenta less
methylated than blood but the majority of this difference is
due to the Xi. The Xi appeared to show the greatest decrease
in methylation at promoters, however, the limited number of
assays and the combination of two methylation detection tech-
niques precludes a deﬁnitive conclusion as to the degree of Xi
placental hypomethylation between regions. MeXiP is the
clear pattern for X-linked CpG island promoters, as well as
a subset of non-island promoters. This trend is maintained
for the intragenic and intergenic regions for CpG islands,
likely due to the presence of unannotated gene promoters.
The exclusion of possible unannotated promoters (regions
demonstrating MeXiP) resulted in higher intragenic and inter-
genic methylation on the Xa than the Xi for both blood and
placenta regardless of CpG density.
The observation of MeXiP at CpG island promoters is con-
sistent with previous array-based studies that have shown an
inverse correlation between DNA methylation and expression
at island promoters (10). The regulatory nature of the promoter
methylation has been demonstrated by the removal of methyl-
ation through 5-azacytidine treatment resulting in the reactiva-
tion of genes on the X chromosome (31). In contrast, it has been
suggested that a consequence of transcription may be sub-
sequent gene-body methylation, a ﬁnding supported by higher
intragenicXamethylationdetectedbyarray-basedtechnologies
(21,23,32). If gene body methylation were reﬂecting transcrip-
tion then the methylation patterns of intragenic and intergenic
regions should be very different. We observe, however, a
similar reduction in methylation in intergenic regions on the
Xi compared with the Xa, consistent with the observation that
5 of the 17 most consistently Xa methylated SNPs examined
by Hellman and Chess (23) were located outside of the gene
bodies. Therefore, the relative Xa:Xi hypermethylation cannot
be solely attributed to the transcription of currently annotated
genes. Hansen (33) has previously proposed that the Xa and
Xi are methylated by different de novo methyltransferases
based on the hypomethylation of LINE1 elements on the Xi
but not the Xa or autosomes in ICF syndrome cells (33,34).
While ICF syndrome cells, which have a mutation in
DMNT3B, also show hypomethylation of X-linked promoters
and several classes of satellite elements no reduction in DNA
methyltransferases has been observed in the placenta (35–37).
The lower methylation in placenta could impact the stability
of silencing. Indeed, some normally silent repetitive elements,
imprinted genes and individual X-linked genes have been
shown to become expressed in placenta (38–41). Expression
of both alleles of the X-linked gene G6PD were observed in
a subset of placental cells, and when chorionic villi cells
were used to create somatic cell hybrids some hybrids
showed global X chromosome reactivation, a process which
normally occurs only during oogenesis (38,42,43). There
does not, however, appear to be a general over-expression of
placental X-linked genes compared with other somatic
tissues, thus the synergistic silencing action of chromatin
changes and the non-coding XIST RNA are apparently sufﬁ-
cient to maintain the majority of placental X inactivation
(40). Nonetheless, the decreased placental methylation
should be considered when using assays based on methylation,
such as those to evaluate skewing of X inactivation (38).
CpG islands are generally unmethylated, but genome-wide
studies have demonstrated tissue-speciﬁc hypermethylation
of some island promoter regions as well as hypermethylation
in cancer (44–46). While we did not observe a signiﬁcant
methylation difference in autosomal promoter methylation
between blood and placenta, a recent study comparing blood
and placenta reported many regions showing tissue-speciﬁc
differences on chromosomes 13, 18 and 21, with hypomethy-
lation being more common than hypermethylation (47). In a
minority of our X-linked assays (4 pyrosequencing assays
and 14 Illumina GoldenGate assays out of a total of 114) the
level of methylation was signiﬁcantly (P , 0.05) higher in
placenta than in blood for at least one sex, perhaps reﬂecting
sex and tissue-speciﬁc gene silencing on the X. Little is
known about the methylation at tissue-speciﬁc island promo-
ters on the X except for AR which has been shown to maintain
MeXiP in a variety of tissues forming the basis of a commonly
used methylation based X inactivation skewing assay (48).
Human Molecular Genetics, 2009, Vol. 18, No. 19 3549Here we have shown that reduced DNA methylation in the
human placenta is not consistent across the genome, rather it
occurs in repetitive elements and across the X chromosome.
The Xa consistently showed less decrease in placental methyl-
ation than the Xi, even when the Xa was equivalently or more
methylated than the Xi. This suggests that the facultative het-
erochromatin of the Xi behaves similarly to repetitive elements
in the placenta. As previously reported, we observe that
X-linked island promoters are methylated in females not
males, a pattern which we have termed MeXiP. Intriguingly,
MeXiP is also seen for 20% of non-island promoters as well
as 50% of non-promoter islands, which we attribute to unanno-
tated promoters. Outside of promoters, the Xa is slightly more
methylated than the Xi in both intragenic and intergenic
regions, with intragenic regions tending to be more methylated
than intergenic regions. Further study is required to determine
the contribution of transcription or other processes to the estab-
lishment and/or maintenance of such methylation patterns.
MATERIALS AND METHODS
Sample collection
Placentas were collected with consent from pregnancies deliv-
ered at British Columbia’s Women’s Hospital. Placentas from
females (n ¼ 11) were an average of 37.8 months gestational
age and had an average maternal age of 34.6 years. Placentas
frommales(n ¼ 15)wereanaverageof38.9monthsgestational
age and had an average maternal age of 35.2 years. Blood
samples were from anonymous males (n ¼ 6) and females
(n ¼ 6) ranging in age from 2 to 49 years for males and 22 to
44 years for females. Ethics approval was obtained from the
University of British Columbia clinical research ethics board.
DNA extraction and bisulﬁte conversion
DNA was extracted from fresh whole blood samples following
a standard salting out DNA extraction (49). After removal of
amniotic and chorionic membranes DNA was extracted from
two separate samples of chorionic villi from the fetal side of
the placenta as outlined in Penaherrera et al. (50). Five
hundred nanograms of DNA were then used for a bisulﬁte con-
version following the instructions in the EZ DNA Methylation
Gold Kit (Zymo Research Corporation). Complete conversion
was conﬁrmed using the internal bisulﬁte conversion controls
in each pyrosequencing assay and the bisulﬁte conversion
control summary graph for the Illumina GoldenGate panel.
Illumina goldengate panel
SampleswereappliedtoanIlluminaGoldenGatebeadarraythat
assays 1505 CpG sites located in promoters across the genome.
Eighty-four of these sites were located on the X chromosome
and associated with 39 X-linked genes. The location of autoso-
Figure 4. Summary of methylation analyses showing placental reduction in methylation predominately on the Xi. Data from both Illumina and pyrosequencing
are combined and shown separately for CpG island (HC & IC) assays and non-island (LC) assays in promoter regions, intragenic regions (includes both introns
and exons) and intergenic regions. In order to combine Illumina GoldenGate data (which is only for promoter regions), we converted beta-values to percent
methylation. These values were consistent with pyrosequencing data at the low range, but generally higher than pyrosequencing in the midrange, accounting
for the Xi value over 1 for promoters. Percent methylation is the average of all CpGs in the indicated region. Percent methylation is divided into Xa and Xi
with grey bars representing methylation in blood and black bars for placenta with the average percent methylation value written in each bar. The summary
of the methylation trends for the different regions is described below each bar graph. Signiﬁcance calculated using Mann–Whitney test with signiﬁcance
shown as P ¼ 0.01 to 0.05 ( ), P ¼ 0.01 to 0.001 (  ) and P , 0.001 (   ).
3550 Human Molecular Genetics, 2009, Vol. 18, No. 19mal CpGs assayed on this panel ranged from 1499 bp upstream
of the transcription start site (TSS) to 497 bp downstream. The
X chromosome assays were located up to 1681 bp upstream of
the TSS and 472 bp downstream. Data underwent average
normalization using the Methylation Module (version 3.2.0)
in BeadStudio (version 3.1.3.0 Illumina, Inc.) to ensure that
the background intensities of each array were comparable.
The heatmap and dendrogram in Figure 2 were generated
usingtheManhattanHierarchicalClusterMetricinBeadStudio.
Pyrosequencing
Pyrosequencing was performed using a Pyromark ID machine
and the PyroGoldSQA reagent kit (Biotage). Each 25 mL pyro-
sequencing PCR contained the following ﬁnal concentration of
reagents: 1  PCR Buffer (Qiagen), 0.2 mM dNTPs, 0.025U
HotStart Taq DNA Polymerase (Qiagen), 0.25 mM forward
primer, 0.25 mM reverse primer and 25 ng bisulﬁte converted
DNA. Cycling conditions for each assay were the same for all
primers except for the annealing temperature which is listed
for each assay individually in Supplementary Material,
Table S2. Cycling conditions were: 958C for 15 min, 50
cycles of 948C for 30 s, annealing temperature (listed in Sup-
plementaryMaterial,TableS2)for30 s,728Cfor60 s,followed
by a ﬁnal step of 728C for 10 min. Template preparation and
pyrosequencing was then done according to Tost and Gut with
sequencing primers listed in Supplementary Material,
Table S2 (51). Global methylation of LINE1 elements was per-
formed using the LINE1 assay from Biotage with PCR and
cycling conditions as speciﬁed by the supplier. The UCSC
Genome Browser was used to compare non-promoter regions
against four histone modiﬁcations (H2AK9ac, H2BK5ac,
H3K18ac, H3K36ac) that are concentrated around the TSS
and eight histone modiﬁcations (H2BK12ac, H3K4ac,
H4K5ac, H4K8ac, H4K12ac, H2BK20ac, H2BK120ac,
H4K16ac) that are elevated in promoters and the transcribed
regionsof activegenes (12,25).Four histone methylation modi-
ﬁcations(H3K4me1,H3K4me2,H3K4me3,H2A.Z)previously
found to be in promoter regions were also examined (26).
Statistical analysis
Statistical analysis of the Illumina GoldenGate panel was per-
formed using the Mann–Whitney test as calculated by Graph-
Pad prism. For the comparison of Illumina Golden Gate results
the data were analyzed separately for CpG islands and non-
islands based on information from the manufacturer. Male
methylation levels were used as the methylation level of the
Xa. Since the methylation level obtained from females is
the average of both Xs this was multiplied by two and then
the Xa methylation was subtracted resulting in the calculated
amount of methylation on the Xi.
CpG density deﬁnitions used
The deﬁnition of a CpG island used by Illumina and UCSC to
deﬁne a CpG island (GC content .50%, a ratio of greater than
0.6 for ObservedCpG/ExpectedCpG and a length .200 bp) is
the same deﬁnition ﬁrst proposed by Gardiner-Garden and
Frommer in 1987 (11). In a recent genome-wide analysis of
promoter methylation Weber et al. (10) introduced three
CpG density classes, the strong CpG islands (high CpG
density or HC) and the non-CpG islands (low or LC) as well
as an intermediate class (IC). To ensure that all potential
regions of CpG islands were recognized in this study we
have also classiﬁed CpG islands based on these three density
classes. Each class was deﬁned as follows, HC, .55% GC
content, .0.75 ObservedCpG/ExpectedCpG and a length
.500 bp; LC had a ObservedCpG/ExpectedCpG ratio ,0.48
and were shorter than 500 bp. Regions which were neither
HC or LC were classiﬁed as IC. Using this system most
regions classiﬁed as CpG islands by UCSC are deﬁned as
HCs, whereas only approximately one-quarter of ICs would
be classiﬁed by UCSC as islands (10).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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